Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2018

Filing Date
Filed February 21, 2019
Period End
December 31, 2018
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 21, 2019. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies, built largely on its rHuPH20 enzyme platform.

Its ENHANZE drug delivery technology is licensed to nine collaborations, and it has one marketed product, Hylenex recombinant. Its lead proprietary candidate, PEGPH20, is in a Phase 3 trial (HALO 109-301) in stage IV pancreatic ductal adenocarcinoma. In November 2018 the FDA agreed to change the primary endpoint of that trial to overall survival alone, and the company projects the 330 OS events needed for the final analysis will be reached between August and November 2019.

Financially, total revenues fell to $151.9 milliona in 2018 from $316.6 million in 2017, and the company reported a net loss of $80.3 million, or $0.56 per share, compared with net income of $63.0 million in 2017. Revenue in 2018 was driven by royalties of $79.0 million and collaboration revenue of $44.6 million, down from $202.7 million in 2017, which included large upfront license fees. Operating cash flow was negative $49.5 million, and cash, cash equivalents and marketable securities totaled $354.5 million at year-end.

Long-term debt is concentrated in the $150 millionb Royalty-backed Loan and a Loan Agreement with Oxford and SVB, and the company states its current cash should fund operations for at least the next twelve months. Investors should weigh the company's reliance on collaboration payments and royalties against its ongoing PEGPH20 spending, which research and development expenses of $150.3 million in 2018 reflect, and the pending outcome of the HALO-301 trial. The filing also notes that Roche and Baxalta are depleting inventory ahead of manufacturing transitions, which lowered bulk rHuPH20 sales in 2018.

Key Highlights

  1. Total revenues were $151.9 million in 2018, down from $316.6 million in 2017, with royalties rising to $79.0 million from $63.5 million.
  2. Net loss was $80.3 million ($0.56 per share) in 2018, compared with net income of $63.0 million in 2017.
  3. Cash, cash equivalents and marketable securities were $354.5 million at December 31, 2018, down from $469.2 million a year earlier.
  4. Phase 3 HALO-301 trial of PEGPH20 in stage IV pancreatic cancer changed its primary endpoint to overall survival alone; 330 OS events are projected for the final analysis between August and November 2019.
  5. Research and development expenses were $150.3 million in 2018, with PEGPH20 program spending of $131.1 million.
  6. In February 2019, argenx agreed to an ENHANZE license with a $30.0 million upfront payment, and Roche's October 2018 agreement included a $25.0 million upfront payment.
  7. Roche accounted for 72% of 2018 total revenues, and the company's Royalty-backed Loan of $150 million is repaid from royalties under the Roche and Baxalta collaborations.

Follow one dollar

For each $1.00 of revenue in FY2018, Halozyme Therapeutics lost $0.53.

  1. Revenue$151.9M100.0%
  2. Cost of revenue−$10.1M6.7%
  3. Gross profit$141.7M93.3%
  4. Operating costs−$211.1M139.0%
  5. Operating income−$69.3M45.7%
  6. Interest, other & tax−$11.0M7.2%
  7. Net income−$80.3M52.9%
Computed from 10-KFY2018filed February 21, 2019Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2018 against FY2017

Line itemFY2018FY2017Change
Revenue$151.86M$316.61M−52.0%
Cost of Revenue$10.14M$31.15M−67.5%
Gross Profit$141.73M$285.46M−50.4%
R&D Expenses$150.25M$150.64M−0.3%
SG&A Expenses$60.80M$53.82M+13.0%
Operating Expenses$221.19M$235.61M−6.1%
Operating Income-$69.33M$81.00M−185.6%
Interest Expense$18.04M$21.98M−17.9%
Net Income-$80.33M$62.97M−227.6%
EPS (Basic)$-0.56$0.46−221.7%
EPS (Diluted)$-0.56$0.45−224.4%
Shares Outstanding (Basic)143.60M136.42M+5.3%
Shares Outstanding (Diluted)143.60M139.07M+3.3%

Frequently Asked Questions

  1. What drove the decline in revenue in 2018?

    Total revenues fell to $151.9 million from $316.6 million. Revenues under collaborative agreements dropped to $44.6 million from $202.7 million, because 2017 included large upfront license fees and milestones from Roche, BMS, Alexion and Janssen. Product sales, net also fell to $28.2 million from $50.4 million, mainly because Roche and Baxalta depleted existing inventory of bulk rHuPH20 ahead of planned transitions to new manufacturing facilities. Royalty revenue increased to $79.0 million.

  2. What is the status of the PEGPH20 Phase 3 trial?

    The HALO-301 trial in stage IV pancreatic ductal adenocarcinoma was fully enrolled with approximately 500 patients by the end of 2018. In November 2018, the FDA agreed to change the primary endpoint from PFS and OS to OS alone, and the planned PFS interim analysis will not be conducted. The company projects the target of 330 OS events will be reached between August and November 2019.

  3. How is the company funded, and does it have debt obligations?

    The company reported $354.5 million in cash, cash equivalents and marketable securities at year-end 2018 and states this is sufficient to fund operations for at least the next twelve months. Long-term debt, net, was $126.4 million present value including current portion. The $150 million Royalty-backed Loan at Halozyme Royalty, which had an outstanding balance of $85.0 million, is repaid from royalties, and the Oxford and SVB Loan Agreement had an outstanding term loan balance of $41.4 million. The company also states it may need to raise additional capital in the future.

  4. Which products generate the company's current revenue?

    The company has one marketed proprietary product, Hylenex recombinant, which generated $15.0 million in 2018 sales. Its collaboration partners generate royalties on products including Herceptin SC, MabThera SC (RITUXAN HYCELA in the U.S.) and HYQVIA. Royalties totaled $79.0 million in 2018, and bulk rHuPH20 sales to collaborators totaled $12.7 million.